Albumin Excretion Rate and Cardiovascular Risk

TABLE 2

AER by peak response curve morphology group

Model Normal peak Early nondominant peak Early dominant peak P for trend R2 (%)
AER (μg/min)
    Unadjusted 3.69 (3.20–4.07) 7.22 (5.47–9.53) 12.56 (7.80–20.20) <0.001 18.3
    Age and sex adjusted 3.80 (3.20–4.50) 6.73 (5.84–7.76) 11.94 (9.07–15.72) <0.001 24.2
    Fully adjusted model* 4.17 (3.45–5.04) 7.34 (6.28–8.59) 12.93 (9.45–17.70) <0.001 29.5
Fully adjusted AER in selected populations (μg/min)
    No diabetes 4.49 (3.78–5.34) 6.71 (5.72–7.87) 10.03 (7.20–13.97) <0.001 26.4
    With diabetes 3.71 (2.33–6.17) 7.56 (5.38–10.62) 15.38 (7.98–29.63) 0.004 44.1
    Normotensive 3.71 (3.03–4.53) 5.60 (4.58–6.84) 8.45 (5.64–12.66) 0.001 18.2
    Hypertensive 4.90 (3.31–7.24) 9.70 (7.54–12.49) 19.22 (11.73–31.47) <0.001 34.5
    No anti-HTs 3.70 (2.96–4.54) 5.59 (4.57–6.84) 8.44 (5.62–12.66) 0.002 18.2
    No DM/no anti-HTs 1.43 (2.26–7.68) 5.78 (3.09–10.81) 8.01 (3.86–16.59) 0.009 24.7
  • Data are means (95% CI) after adjustment for potential confounding and mechanistic factors stratified by peak response curve morphology group. R2, total variance explained by the model; hypertensive, systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg or taking antihypertensive agents (HTs); no anti-HTs, patients taking no vasoactive medications (including antihypertensives, antianginals, sulfonylureas, or thiazolidinediones); no DM/no anti-HTs, patients with no diagnosis of diabetes and taking no vasoactive medications.

  • *

    * Adjusted for age, sex, daytime ambulatory systolic blood pressure, weight, fasting glucose level, fasting triglyceride level, and smoker status.

This Article

  1. Diabetes vol. 54 no. 6 1816-1822